Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967196 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04967196: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT04967196 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04967196, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I trial identifies the best dose of ipilimumab that can be administered through the DoseConnect™ device followed by nivolumab in treating patients with stage III melanoma that cannot be removed by surgery (unresectable) or stage IV melanoma that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- PROCEDURE Biospecimen Collection
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- PROCEDURE Lymph Node Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04967196
The ClinicalTrials.gov registry entry for NCT04967196 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04967196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04967196 about?
NCT04967196 is a clinical study titled "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma". This phase I trial identifies the best dose of ipilimumab that can be administered through the DoseConnect™ device followed by nivolumab in treating patients with stage III melanoma that cannot be removed by surgery (unresectable) or stage IV melanoma that has spread to other places in the body (met...
What is the current status of trial NCT04967196?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-09-16. Estimated completion is 2024-04-17.
What interventions are being tested in trial NCT04967196?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Lymph Node Assessment (PROCEDURE).
Who is sponsoring clinical trial NCT04967196?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.